Published in Antimicrob Agents Chemother on July 20, 2009
The oligo-acyl lysyl antimicrobial peptide C₁₂K-2β₁₂ exhibits a dual mechanism of action and demonstrates strong in vivo efficacy against Helicobacter pylori. Antimicrob Agents Chemother (2011) 0.87
In vitro characterization of the anti-bacterial activity of SQ109 against Helicobacter pylori. PLoS One (2013) 0.87
Recombinant expression of two bacteriophage proteins that lyse clostridium perfringens and share identical sequences in the C-terminal cell wall binding domain of the molecules but are dissimilar in their N-terminal active domains. J Agric Food Chem (2010) 0.86
Efficacy of the antimicrobial peptide TP4 against Helicobacter pylori infection: in vitro membrane perturbation via micellization and in vivo suppression of host immune responses in a mouse model. Oncotarget (2015) 0.80
Experimental conditions that enhance potency of an antibacterial oligo-acyl-lysyl. Antimicrob Agents Chemother (2010) 0.79
The synthetic amphipathic peptidomimetic LTX109 is a potent fungicide that disturbs plasma membrane integrity in a sphingolipid dependent manner. PLoS One (2013) 0.76
The complete genome sequence of the gastric pathogen Helicobacter pylori. Nature (1997) 34.00
Unidentified curved bacilli in the stomach of patients with gastritis and peptic ulceration. Lancet (1984) 32.58
Genomic-sequence comparison of two unrelated isolates of the human gastric pathogen Helicobacter pylori. Nature (1999) 19.34
Antimicrobial peptides: pore formers or metabolic inhibitors in bacteria? Nat Rev Microbiol (2005) 13.69
Helicobacter pylori infection and gastric carcinoma among Japanese Americans in Hawaii. N Engl J Med (1991) 11.98
Helicobacter pylori infection and gastric lymphoma. N Engl J Med (1994) 10.26
Current concepts in the management of Helicobacter pylori infection: the Maastricht III Consensus Report. Gut (2006) 9.03
A standardized mouse model of Helicobacter pylori infection: introducing the Sydney strain. Gastroenterology (1997) 7.72
American College of Gastroenterology guideline on the management of Helicobacter pylori infection. Am J Gastroenterol (2007) 7.49
Mechanism of the binding, insertion and destabilization of phospholipid bilayer membranes by alpha-helical antimicrobial and cell non-selective membrane-lytic peptides. Biochim Biophys Acta (1999) 5.85
Sequential therapy versus standard triple-drug therapy for Helicobacter pylori eradication: a randomized trial. Ann Intern Med (2007) 5.62
Characterization of urease from Campylobacter pylori. J Clin Microbiol (1988) 5.57
Diversity of antimicrobial peptides and their mechanisms of action. Biochim Biophys Acta (1999) 4.71
The relationship among previous antimicrobial use, antimicrobial resistance, and treatment outcomes for Helicobacter pylori infections. Ann Intern Med (2003) 4.65
Meta-analysis: sequential therapy appears superior to standard therapy for Helicobacter pylori infection in patients naive to treatment. Ann Intern Med (2008) 3.72
Activation of beta-catenin by carcinogenic Helicobacter pylori. Proc Natl Acad Sci U S A (2005) 3.52
Metronidazole resistance in Helicobacter pylori is due to null mutations in a gene (rdxA) that encodes an oxygen-insensitive NADPH nitroreductase. Mol Microbiol (1998) 3.44
Helicobacter pylori infection and the risk for duodenal and gastric ulceration. Ann Intern Med (1994) 3.19
The complete genome sequence of a chronic atrophic gastritis Helicobacter pylori strain: evolution during disease progression. Proc Natl Acad Sci U S A (2006) 3.07
Antimicrobial defense and persistent infection in insects. Science (2008) 2.73
Evaluation of the bactericidal activity of beta-lactam antibiotics on slowly growing bacteria cultured in the chemostat. Antimicrob Agents Chemother (1986) 2.68
Tryptophan- and arginine-rich antimicrobial peptides: structures and mechanisms of action. Biochim Biophys Acta (2006) 2.14
European multicentre survey of in vitro antimicrobial resistance in Helicobacter pylori. Eur J Clin Microbiol Infect Dis (2001) 2.10
Rapid urea hydrolysis by gastric Campylobacters. Lancet (1985) 2.06
The complete genome sequence of Helicobacter pylori strain G27. J Bacteriol (2008) 2.05
The role of internal urease in acid resistance of Helicobacter pylori. Gastroenterology (1998) 2.02
The role of cathelicidins in the innate host defenses of mammals. Curr Issues Mol Biol (2005) 1.94
The true division and death rates of Salmonella typhimurium in the mouse spleen determined with superinfecting phage P22. Br J Exp Pathol (1968) 1.89
Guidelines for the management of Helicobacter pylori infection. Ad Hoc Committee on Practice Parameters of the American College of Gastroenterology. Am J Gastroenterol (1998) 1.78
Effectiveness of Helicobacter pylori therapies in a clinical practice setting. Arch Intern Med (1999) 1.64
Metabolic activities of metronidazole-sensitive and -resistant strains of Helicobacter pylori: repression of pyruvate oxidoreductase and expression of isocitrate lyase activity correlate with resistance. J Bacteriol (1996) 1.64
Tight binding of clarithromycin, its 14-(R)-hydroxy metabolite, and erythromycin to Helicobacter pylori ribosomes. Antimicrob Agents Chemother (1994) 1.62
Helicobacter pylori eradication therapy is more effective in peptic ulcer than in non-ulcer dyspepsia. Eur J Gastroenterol Hepatol (2001) 1.58
Improved antimicrobial peptides based on acyl-lysine oligomers. Nat Biotechnol (2007) 1.53
Review article: the treatment of refractory Helicobacter pylori infection. Aliment Pharmacol Ther (2003) 1.49
Mechanisms of acid resistance due to the urease system of Helicobacter pylori. Gastroenterology (2002) 1.47
Secondary resistance among 554 isolates of Helicobacter pylori after failure of therapy. Eur J Clin Microbiol Infect Dis (2000) 1.45
Basis for selectivity of cationic antimicrobial peptides for bacterial versus mammalian membranes. J Biol Chem (2005) 1.40
Antibacterial properties of dermaseptin S4 derivatives with in vivo activity. Antimicrob Agents Chemother (2002) 1.36
Differential regulation of amidase- and formamidase-mediated ammonia production by the Helicobacter pylori fur repressor. J Biol Chem (2002) 1.33
Proton pump inhibitor, clarithromycin and either amoxycillin or nitroimidazole: a meta-analysis of eradication of Helicobacter pylori. Aliment Pharmacol Ther (2000) 1.33
Tryptophan-rich antimicrobial peptides: comparative properties and membrane interactions. Biochem Cell Biol (2002) 1.26
Antimicrobial peptides from hylid and ranin frogs originated from a 150-million-year-old ancestral precursor with a conserved signal peptide but a hypermutable antimicrobial domain. Eur J Biochem (2003) 1.25
Bacterial membranes as predictors of antimicrobial potency. J Am Chem Soc (2008) 1.22
Efficacy of levofloxacin-based rescue therapy for Helicobacter pylori infection after standard triple therapy: a randomized controlled trial. J Antimicrob Chemother (2009) 1.21
Antimicrobial peptides from skin secretions of Chinese red belly toad Bombina maxima. Peptides (2002) 1.16
High prevalence of Helicobacter pylori infection with dual resistance to metronidazole and clarithromycin in Hong Kong. Aliment Pharmacol Ther (2000) 1.15
Generation times of Proteus mirabilis and Escherichia coli in experimental infections. Chemotherapy (1973) 1.14
Gram-negative outer and inner membrane models: insertion of cyclic cationic lipopeptides. J Phys Chem B (2007) 1.12
2-week triple therapy for Helicobacter pylori infection is better than 1-week in clinical practice: a large prospective single-center randomized study. Helicobacter (2006) 1.10
Effectiveness of Helicobacter pylori eradication treatments in a primary care setting in Italy. Aliment Pharmacol Ther (2002) 1.10
The lipopolysaccharide of Bordetella bronchiseptica acts as a protective shield against antimicrobial peptides. Infect Immun (1998) 1.10
Primary antibiotic resistance in Helicobacter pylori strains isolated in northern and central Italy. Aliment Pharmacol Ther (2007) 1.09
Evolution of Helicobacter pylori therapy from a meta-analytical perspective. Helicobacter (2007) 1.07
Analogous oligo-acyl-lysines with distinct antibacterial mechanisms. FASEB J (2008) 1.05
Mode of action of the lanthionine-containing peptide antibiotics duramycin, duramycin B and C, and cinnamycin as indirect inhibitors of phospholipase A2. Biochem Pharmacol (1991) 1.04
Quadruple therapy with furazolidone for retreatment in patients with peptic ulcer disease. World J Gastroenterol (2008) 1.02
In vitro killing of penicillin-susceptible, -intermediate, and -resistant strains of Streptococcus pneumoniae by cefotaxime, ceftriaxone, and ceftizoxime: a comparison of bactericidal and inhibitory activity with achievable CSF levels. Diagn Microbiol Infect Dis (1995) 1.00
The post-antibiotic effect of antimicrobial combinations in a neutropenic murine thigh infection model. J Antimicrob Chemother (1993) 0.98
Empirical rescue therapy after Helicobacter pylori treatment failure: a 10-year single-centre study of 500 patients. Aliment Pharmacol Ther (2007) 0.97
Antiplasmodial activity of lauryl-lysine oligomers. Antimicrob Agents Chemother (2007) 0.96
Structure-activity relationships of antibacterial acyl-lysine oligomers. Chem Biol (2008) 0.95
Frame-shift mutations in NAD(P)H flavin oxidoreductase encoding gene (frxA) from metronidazole resistant Helicobacter pylori ATCC43504 and its involvement in metronidazole resistance. FEMS Microbiol Lett (2000) 0.94
Rationale for the design of shortened derivatives of the NK-lysin-derived antimicrobial peptide NK-2 with improved activity against Gram-negative pathogens. J Biol Chem (2007) 0.93
A systematic comparison of triple therapies for treatment of Helicobacter pylori infection with proton pump inhibitor/ ranitidine bismuth citrate plus clarithromycin and either amoxicillin or a nitroimidazole. Aliment Pharmacol Ther (2001) 0.93
One-week once-daily triple therapy with esomeprazole, moxifloxacin, and rifabutin for eradication of persistent Helicobacter pylori resistant to both metronidazole and clarithromycin. Helicobacter (2008) 0.93
Who's Winning the War? Molecular Mechanisms of Antibiotic Resistance in Helicobacter pylori. Curr Drug ther (2008) 0.92
Pore formation by nisin involves translocation of its C-terminal part across the membrane. Biochemistry (1998) 0.92
The mode of action of metronidazole in Helicobacter pylori: futile cycling or reduction? J Antimicrob Chemother (1998) 0.89
Efficacy of metronidazole as second-line drug for the treatment of Helicobacter pylori Infection in the Japanese population: a multicenter study in the Tokyo Metropolitan Area. Helicobacter (2006) 0.89
Investigating the effects of positive charge and hydrophobicity on the cell selectivity, mechanism of action and anti-inflammatory activity of a Trp-rich antimicrobial peptide indolicidin. FEMS Microbiol Lett (2009) 0.88
Furazolidone, amoxicillin, bismuth and rabeprazole quadruple rescue therapy for the eradication of Helicobacter pylori. World J Gastroenterol (2009) 0.88
Impact of self-assembly properties on antibacterial activity of short acyl-lysine oligomers. Antimicrob Agents Chemother (2008) 0.87
Pharmacodynamic effects of antibiotics and acid pump inhibitors on Helicobacter pylori. Antimicrob Agents Chemother (1997) 0.86
One-week once-daily triple therapy with esomeprazole, levofloxacin and azithromycin compared to a standard therapy for Helicobacter pylori eradication. Dig Liver Dis (2005) 0.85
Two-week dual vs. one-week triple therapy for cure of Helicobacter pylori infection in primary care: a multicentre, randomized trial. Aliment Pharmacol Ther (1999) 0.83
Absence of a post-antibiotic effect (PAE) of beta-lactams against Helicobacter pylori NCTC 11637. J Antimicrob Chemother (1998) 0.79
4-day lansoprazole quadruple therapy: a highly effective cure for Helicobacter pylori infection. Am J Gastroenterol (1996) 0.79
[Seven-day omeprazole, clarithromycin, and amoxicillin for the therapy of Helicobacter pylori infection]. Gastroenterol Hepatol (1998) 0.78
Sequential therapy for Helicobacter pylori: time to consider making the switch? JAMA (2008) 0.78
Successful isolation of Helicobacter pylori after prolonged incubation from a patient with failed eradication therapy. World J Gastroenterol (2009) 0.75
The complete genome sequence of Helicobacter pylori strain G27. J Bacteriol (2008) 2.05
Gene expression profiling of Helicobacter pylori reveals a growth-phase-dependent switch in virulence gene expression. Infect Immun (2003) 2.02
This is not your mother's repressor: the complex role of fur in pathogenesis. Infect Immun (2009) 1.71
Improved antimicrobial peptides based on acyl-lysine oligomers. Nat Biotechnol (2007) 1.53
Iron and pH homeostasis intersect at the level of Fur regulation in the gastric pathogen Helicobacter pylori. Infect Immun (2006) 1.48
Antibacterial properties of dermaseptin S4 derivatives with in vivo activity. Antimicrob Agents Chemother (2002) 1.36
Phosphorylation-independent effects of CagA during interaction between Helicobacter pylori and T84 polarized monolayers. J Infect Dis (2004) 1.32
Vibrio cholerae strain typing and phylogeny study based on simple sequence repeats. J Clin Microbiol (2006) 1.29
Antimicrobial peptide mimics for improved therapeutic properties. Biochim Biophys Acta (2008) 1.28
Polymorphism in the CagA EPIYA motif impacts development of gastric cancer. J Clin Microbiol (2009) 1.27
Bacterial membranes as predictors of antimicrobial potency. J Am Chem Soc (2008) 1.22
Inducible nitric oxide synthetase genotype and Helicobacter pylori infection affect gastric cancer risk. World J Gastroenterol (2012) 1.22
Structural requirements for potent versus selective cytotoxicity for antimicrobial dermaseptin S4 derivatives. J Biol Chem (2002) 1.19
Expanding the Helicobacter pylori genetic toolbox: modification of an endogenous plasmid for use as a transcriptional reporter and complementation vector. Appl Environ Microbiol (2007) 1.18
Vibrio cholerae hemagglutinin/protease degrades chironomid egg masses. Appl Environ Microbiol (2003) 1.16
Adult non-biting midges: possible windborne carriers of Vibrio cholerae non-O1 non-O139. Environ Microbiol (2005) 1.14
Epidemiological link between gastric disease and polymorphisms in VacA and CagA. J Clin Microbiol (2009) 1.13
ToxR interferes with CRP-dependent transcriptional activation of ompT in Vibrio cholerae. Mol Microbiol (2002) 1.07
Effects of acyl versus aminoacyl conjugation on the properties of antimicrobial peptides. Antimicrob Agents Chemother (2005) 1.06
In vitro antiplasmodium effects of dermaseptin S4 derivatives. Antimicrob Agents Chemother (2002) 1.06
Sodium chloride affects Helicobacter pylori growth and gene expression. J Bacteriol (2008) 1.05
Analogous oligo-acyl-lysines with distinct antibacterial mechanisms. FASEB J (2008) 1.05
Frequency of antibiotic resistance in Helicobacter pylori strains isolated from the northern population of Iran. J Microbiol (2011) 1.04
A single nucleotide change affects fur-dependent regulation of sodB in H. pylori. PLoS One (2009) 1.04
Profiling of microdissected gastric epithelial cells reveals a cell type-specific response to Helicobacter pylori infection. Gastroenterology (2004) 1.03
Polymorphism in the interleukin-17A promoter contributes to gastric cancer. World J Gastroenterol (2013) 1.02
Polymorphisms in the intermediate region of VacA impact Helicobacter pylori-induced disease development. J Clin Microbiol (2010) 1.02
Change is good: variations in common biological mechanisms in the epsilonproteobacterial genera Campylobacter and Helicobacter. Microbiol Mol Biol Rev (2011) 1.01
A Tale of Two Toxins: Helicobacter Pylori CagA and VacA Modulate Host Pathways that Impact Disease. Front Microbiol (2010) 1.00
Diet synergistically affects helicobacter pylori-induced gastric carcinogenesis in nonhuman primates. Gastroenterology (2009) 1.00
Helicobacter pylori homB, but not cagA, is associated with gastric cancer in Iran. J Clin Microbiol (2011) 0.99
Role of the conformational rigidity in the design of biomimetic antimicrobial compounds. Angew Chem Int Ed Engl (2010) 0.98
Fur activates expression of the 2-oxoglutarate oxidoreductase genes (oorDABC) in Helicobacter pylori. J Bacteriol (2012) 0.97
Structure-activity relationships of antibacterial acyl-lysine oligomers. Chem Biol (2008) 0.95
Phylogeographic origin of Helicobacter pylori determines host-adaptive responses upon coculture with gastric epithelial cells. Infect Immun (2013) 0.95
Antibacterial properties of dermaseptin S4 derivatives under extreme incubation conditions. Antimicrob Agents Chemother (2006) 0.95
Helicobacter pylori apo-Fur regulation appears unconserved across species. J Microbiol (2010) 0.94
A miniature mimic of host defense peptides with systemic antibacterial efficacy. FASEB J (2010) 0.94
Resistance of Porphyromonas gingivalis ATCC 33277 to direct killing by antimicrobial peptides is protease independent. Antimicrob Agents Chemother (2007) 0.94
Cytotoxic necrotizing factor 1 and hemolysin from uropathogenic Escherichia coli elicit different host responses in the murine bladder. Infect Immun (2012) 0.93
Molecular characterization of a catalase-negative methicillin-susceptible Staphylococcus aureus subsp. aureus strain collected from a patient with cutaneous abscess. J Clin Microbiol (2013) 0.93
Antibiotic treatment decreases microbial burden associated with pseudomyxoma peritonei and affects β-catenin distribution. Clin Cancer Res (2013) 0.93
Direct interaction of dermaseptin S4 aminoheptanoyl derivative with intraerythrocytic malaria parasite leading to increased specific antiparasitic activity in culture. J Biol Chem (2002) 0.92
Who's Winning the War? Molecular Mechanisms of Antibiotic Resistance in Helicobacter pylori. Curr Drug ther (2008) 0.92
Detailed analysis of Helicobacter pylori Fur-regulated promoters reveals a Fur box core sequence and novel Fur-regulated genes. Mol Microbiol (2012) 0.92
Analysis of membrane-binding properties of dermaseptin analogues: relationships between binding and cytotoxicity. Biochemistry (2003) 0.92
Activity of dermaseptin K4-S4 against foodborne pathogens. Peptides (2003) 0.92
Detailed in vivo analysis of the role of Helicobacter pylori Fur in colonization and disease. Infect Immun (2010) 0.91
Helicobacter pylori-induced histone modification, associated gene expression in gastric epithelial cells, and its implication in pathogenesis. PLoS One (2010) 0.91
Dietary choice affects Shiga toxin-producing Escherichia coli (STEC) O157:H7 colonization and disease. Proc Natl Acad Sci U S A (2013) 0.91
A chimeric peptide composed of a dermaseptin derivative and an RNA III-inhibiting peptide prevents graft-associated infections by antibiotic-resistant staphylococci. Antimicrob Agents Chemother (2004) 0.90
A core microbiome associated with the peritoneal tumors of pseudomyxoma peritonei. Orphanet J Rare Dis (2013) 0.90
Structural consequences of carboxyamidation of dermaseptin S3. Biochemistry (2002) 0.89
Cell-wall interactions and the selective bacteriostatic activity of a miniature oligo-acyl-lysyl. Biophys J (2009) 0.89
Polymorphism in the Helicobacter pylori CagA and VacA toxins and disease. Gut Microbes (2013) 0.89
Mutagenesis of conserved amino acids of Helicobacter pylori fur reveals residues important for function. J Bacteriol (2010) 0.89
Spatiotemporal analysis of acid adaptation-mediated Vibrio cholerae hyperinfectivity. Infect Immun (2004) 0.88
The Helicobacter pylori Ferric Uptake Regulator (Fur) is essential for growth under sodium chloride stress. J Microbiol (2011) 0.88
In vivo fate and therapeutic efficacy of PF-4/CTF microspheres in an orthotopic human glioblastoma model. FASEB J (2007) 0.88
The oligo-acyl lysyl antimicrobial peptide C₁₂K-2β₁₂ exhibits a dual mechanism of action and demonstrates strong in vivo efficacy against Helicobacter pylori. Antimicrob Agents Chemother (2011) 0.87
In vitro characterization of the anti-bacterial activity of SQ109 against Helicobacter pylori. PLoS One (2013) 0.87
Antibacterial properties and mode of action of a short acyl-lysyl oligomer. Antimicrob Agents Chemother (2009) 0.87
Impact of self-assembly properties on antibacterial activity of short acyl-lysine oligomers. Antimicrob Agents Chemother (2008) 0.87
Identification and characterization of novel Helicobacter pylori apo-fur-regulated target genes. J Bacteriol (2013) 0.86
Curvature instability in a chiral amphiphile self-assembly. Phys Rev Lett (2011) 0.85
Balancing the double-edged sword: metal ion homeostasis and the ulcer bug. Curr Med Chem (2007) 0.85
Design and characterization of a broad -spectrum bactericidal acyl-lysyl oligomer. Chem Biol (2009) 0.85
Unraveling the mechanism of nanotube formation by chiral self-assembly of amphiphiles. J Am Chem Soc (2011) 0.84
Heat acclimation prolongs the time to central nervous system oxygen toxicity in the rat. Possible involvement of HSP72. Brain Res (2003) 0.84
Mechanisms mediating bactericidal properties and conditions that enhance the potency of a broad-spectrum oligo-acyl-lysyl. Antimicrob Agents Chemother (2010) 0.83
The association between non-biting midges and Vibrio cholerae. Environ Microbiol (2008) 0.83
Targeting of nonkaryophilic cell-permeable peptides into the nuclei of intact cells by covalently attached nuclear localization signals. Biochemistry (2002) 0.83
Sensitization of gram-negative bacteria by targeting the membrane potential. FASEB J (2013) 0.83
Enterobacterial common antigen mutants of Salmonella enterica serovar Typhimurium establish a persistent infection and provide protection against subsequent lethal challenge. Infect Immun (2011) 0.83
Lipid complexes with cationic peptides and OAKs; their role in antimicrobial action and in the delivery of antimicrobial agents. Cell Mol Life Sci (2011) 0.83
Nontraditional therapies to treat Helicobacter pylori infection. J Microbiol (2014) 0.82
Genetic analysis of Helicobacter pylori clinical isolates suggests resistance to metronidazole can occur without the loss of functional rdxA. J Antibiot (Tokyo) (2009) 0.82
Effect of peptides bearing nuclear localization signals on therapeutic ultrasound mediated gene delivery. J Gene Med (2008) 0.82
In vitro discriminative antipseudomonal properties resulting from acyl substitution of N-terminal sequence of dermaseptin s4 derivatives. Chem Biol (2007) 0.82
Simultaneous breakdown of multiple antibiotic resistance mechanisms in S. aureus. FASEB J (2013) 0.81
Consequences of N-acylation on structure and membrane binding properties of dermaseptin derivative K4-S4-(1-13). J Biol Chem (2005) 0.81
The ferric uptake regulator of Helicobacter pylori: a critical player in the battle for iron and colonization of the stomach. Future Microbiol (2013) 0.81
Host-defense peptide mimicry for novel antitumor agents. FASEB J (2009) 0.81
Functional studies of cochleate assemblies of an oligo-acyl-lysyl with lipid mixtures for combating bacterial multidrug resistance. FASEB J (2011) 0.80
The geographic origin of Helicobacter pylori influences the association of the homB gene with gastric cancer. J Clin Microbiol (2012) 0.80
Physicochemical properties that enhance discriminative antibacterial activity of short dermaseptin derivatives. Antimicrob Agents Chemother (2006) 0.80
Dynamic HypA zinc site is essential for acid viability and proper urease maturation in Helicobacter pylori. Metallomics (2015) 0.79
Experimental conditions that enhance potency of an antibacterial oligo-acyl-lysyl. Antimicrob Agents Chemother (2010) 0.79
Bacterial capture by peptide-mimetic oligoacyllysine surfaces. Appl Environ Microbiol (2010) 0.79
Random and site-specific mutagenesis of the Helicobacter pylori ferric uptake regulator provides insight into Fur structure-function relationships. Mol Microbiol (2013) 0.79
Structure-toxicity relationship of aminoglycosides: correlation of 2'-amine basicity with acute toxicity in pseudo-disaccharide scaffolds. Bioorg Med Chem (2008) 0.78
Microarray analysis of Shigella flexneri-infected epithelial cells identifies host factors important for apoptosis inhibition. BMC Genomics (2010) 0.78